Residential College | false |
Status | 已發表Published |
Furanodiene enhances the anti-cancer effects of doxorubicin on ERα-negative breast cancer cellsin vitro | |
Zhang-Feng Zhong1; Wen-An Qiang2; Chun-Ming Wang1; Wen Tan3; Yi-Tao Wang1 | |
2016-05 | |
Source Publication | European Journal of Pharmacology |
ISSN | 0014-2999 |
Volume | 774Pages:10-19 |
Abstract | Furanodiene is a natural product isolated fromRhizoma curcumae, and exhibits broad-spectrum anti-cancer activitiesin vitroandin vivo. Our previous study proved that furanodiene could increase growthinhibition of steroidal agent in ERα-positive breast cancer cells, but whether furanodiene can influenceER status is not clear. In this study, we confirmed that furanodiene down-regulated the ERαproteinexpression level and inhibited E2-induced estrogen response element (ERE)-driven reporter plasmidactivity in ERα-positive MCF-7 cells. Actually, ERα-knockdown cells were more sensitive than ERαpo-sitive cells to furanodiene on the cytotoxicity effect. So the anti-cancer effects of furanodiene and non-steroidal agent in breast cancer cells still requires further investigation. Our results showed that fur-anodiene exposure could enhance growth inhibitory effects of doxorubicin in ERα-negative MDA-MB-231 cells and ERα-low expression 4T1 cells. However, furanodiene did not increase the cytotoxicity ofdoxorubicin in ERα-positive breast cancer cells, non-tumorigenic breast epithelial cells, macrophagecells, hepatocytes cells, pheochromocytoma cells and cardiac myoblasts cells. Furanodiene enhances theanti-cancer effects of doxorubicin in ERα-negative breast cancer cells through suppressing cell viabilityvia inducing apoptosis in mitochondria-caspases-dependent and reactive oxygen species-independentmanners. These results indicate that furanodiene may be a promising and safety natural agent for canceradjuvant therapy in the future. |
Keyword | Furanodiene Doxorubicin Combination Breast Cancer Apoptosis |
DOI | 10.1016/j.ejphar.2015.11.039 |
Indexed By | SCIE |
Language | 英語English |
WOS Research Area | Pharmacology & Pharmacy |
WOS Subject | Pharmacology & Pharmacy |
WOS ID | WOS:000370824100002 |
Scopus ID | 2-s2.0-84958862470 |
Fulltext Access | |
Citation statistics | |
Document Type | Journal article |
Collection | Institute of Chinese Medical Sciences |
Corresponding Author | Yi-Tao Wang |
Affiliation | 1.Institute of Chinese Medical Sciences, State Key Laboratory of Quality Research in Chinese Medicine, University of Macau, Macau, China 2.Division of Reproductive Biology Research, Department of Obstetrics and Gynecology, Feinberg School of Medicine at Northwestern University, Chicago, IL,USA 3.School of Pharmacy, Lanzhou University, Lanzhou, Gansu, China |
First Author Affilication | Institute of Chinese Medical Sciences |
Corresponding Author Affilication | Institute of Chinese Medical Sciences |
Recommended Citation GB/T 7714 | Zhang-Feng Zhong,Wen-An Qiang,Chun-Ming Wang,et al. Furanodiene enhances the anti-cancer effects of doxorubicin on ERα-negative breast cancer cellsin vitro[J]. European Journal of Pharmacology, 2016, 774, 10-19. |
APA | Zhang-Feng Zhong., Wen-An Qiang., Chun-Ming Wang., Wen Tan., & Yi-Tao Wang (2016). Furanodiene enhances the anti-cancer effects of doxorubicin on ERα-negative breast cancer cellsin vitro. European Journal of Pharmacology, 774, 10-19. |
MLA | Zhang-Feng Zhong,et al."Furanodiene enhances the anti-cancer effects of doxorubicin on ERα-negative breast cancer cellsin vitro".European Journal of Pharmacology 774(2016):10-19. |
Files in This Item: | There are no files associated with this item. |
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment